Kindred Biosciences, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 3.537 million compared to USD 39.567 million a year ago. Operating loss was USD 8.544 million compared to operating Income of USD 24.413 million a year ago. Net loss was USD 9.128 million compared to net income of USD 24.046 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to basic earnings per share from continuing operations of USD 0.61 a year ago. Diluted loss per share from continuing operations was USD 0.2 compared to diluted earnings per share from continuing operations of USD 0.6 a year ago. For the half year, total revenue was USD 5.932 million compared to USD 40.170 million a year ago. Operating loss was USD 17.710 million compared to operating Income of USD 2.023 million a year ago. Net loss was USD 18.868 million compared to net income of USD 1.285 million a year ago. Basic loss per share from continuing operations was USD 0.44 compared to basic earnings per share from continuing operations of USD 0.03 a year ago.